234 related articles for article (PubMed ID: 9784112)
1. Synthesis and tyrosine kinase inhibitory activity of a series of 2-amino-8H-pyrido[2,3-d]pyrimidines: identification of potent, selective platelet-derived growth factor receptor tyrosine kinase inhibitors.
Boschelli DH; Wu Z; Klutchko SR; Showalter HD; Hamby JM; Lu GH; Major TC; Dahring TK; Batley B; Panek RL; Keiser J; Hartl BG; Kraker AJ; Klohs WD; Roberts BJ; Patmore S; Elliott WL; Steinkampf R; Bradford LA; Hallak H; Doherty AM
J Med Chem; 1998 Oct; 41(22):4365-77. PubMed ID: 9784112
[TBL] [Abstract][Full Text] [Related]
2. In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor.
Panek RL; Lu GH; Klutchko SR; Batley BL; Dahring TK; Hamby JM; Hallak H; Doherty AM; Keiser JA
J Pharmacol Exp Ther; 1997 Dec; 283(3):1433-44. PubMed ID: 9400019
[TBL] [Abstract][Full Text] [Related]
3. 2-Substituted aminopyrido[2,3-d]pyrimidin-7(8H)-ones. structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity.
Klutchko SR; Hamby JM; Boschelli DH; Wu Z; Kraker AJ; Amar AM; Hartl BG; Shen C; Klohs WD; Steinkampf RW; Driscoll DL; Nelson JM; Elliott WL; Roberts BJ; Stoner CL; Vincent PW; Dykes DJ; Panek RL; Lu GH; Major TC; Dahring TK; Hallak H; Bradford LA; Showalter HD; Doherty AM
J Med Chem; 1998 Aug; 41(17):3276-92. PubMed ID: 9703473
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of growth factor-mediated tyrosine phosphorylation in vascular smooth muscle by PD 089828, a new synthetic protein tyrosine kinase inhibitor.
Dahring TK; Lu GH; Hamby JM; Batley BL; Kraker AJ; Panek RL
J Pharmacol Exp Ther; 1997 Jun; 281(3):1446-56. PubMed ID: 9190882
[TBL] [Abstract][Full Text] [Related]
5. Structure-activity relationships for a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors.
Hamby JM; Connolly CJ; Schroeder MC; Winters RT; Showalter HD; Panek RL; Major TC; Olsewski B; Ryan MJ; Dahring T; Lu GH; Keiser J; Amar A; Shen C; Kraker AJ; Slintak V; Nelson JM; Fry DW; Bradford L; Hallak H; Doherty AM
J Med Chem; 1997 Jul; 40(15):2296-303. PubMed ID: 9240345
[TBL] [Abstract][Full Text] [Related]
6. Tyrosine kinase inhibitors. 13. Structure-activity relationships for soluble 7-substituted 4-[(3-bromophenyl)amino]pyrido[4,3-d]pyrimidines designed as inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor.
Thompson AM; Murray DK; Elliott WL; Fry DW; Nelson JA; Showalter HD; Roberts BJ; Vincent PW; Denny WA
J Med Chem; 1997 Nov; 40(24):3915-25. PubMed ID: 9397172
[TBL] [Abstract][Full Text] [Related]
7. In vitro biological characterization and antiangiogenic effects of PD 166866, a selective inhibitor of the FGF-1 receptor tyrosine kinase.
Panek RL; Lu GH; Dahring TK; Batley BL; Connolly C; Hamby JM; Brown KJ
J Pharmacol Exp Ther; 1998 Jul; 286(1):569-77. PubMed ID: 9655904
[TBL] [Abstract][Full Text] [Related]
8. Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor.
Smaill JB; Palmer BD; Rewcastle GW; Denny WA; McNamara DJ; Dobrusin EM; Bridges AJ; Zhou H; Showalter HD; Winters RT; Leopold WR; Fry DW; Nelson JM; Slintak V; Elliot WL; Roberts BJ; Vincent PW; Patmore SJ
J Med Chem; 1999 May; 42(10):1803-15. PubMed ID: 10346932
[TBL] [Abstract][Full Text] [Related]
9. Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors.
Rewcastle GW; Murray DK; Elliott WL; Fry DW; Howard CT; Nelson JM; Roberts BJ; Vincent PW; Showalter HD; Winters RT; Denny WA
J Med Chem; 1998 Feb; 41(5):742-51. PubMed ID: 9513602
[TBL] [Abstract][Full Text] [Related]
10. Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-d]pyrimidines.
Traxler P; Bold G; Frei J; Lang M; Lydon N; Mett H; Buchdunger E; Meyer T; Mueller M; Furet P
J Med Chem; 1997 Oct; 40(22):3601-16. PubMed ID: 9357527
[TBL] [Abstract][Full Text] [Related]
11. Soluble 2-substituted aminopyrido[2,3-d]pyrimidin-7-yl ureas. Structure-activity relationships against selected tyrosine kinases and exploration of in vitro and in vivo anticancer activity.
Schroeder MC; Hamby JM; Connolly CJ; Grohar PJ; Winters RT; Barvian MR; Moore CW; Boushelle SL; Crean SM; Kraker AJ; Driscoll DL; Vincent PW; Elliott WL; Lu GH; Batley BL; Dahring TK; Major TC; Panek RL; Doherty AM; Showalter HD
J Med Chem; 2001 Jun; 44(12):1915-26. PubMed ID: 11384237
[TBL] [Abstract][Full Text] [Related]
12. Tyrosine kinase inhibitors. 12. Synthesis and structure-activity relationships for 6-substituted 4-(phenylamino)pyrimido[5,4-d]pyrimidines designed as inhibitors of the epidermal growth factor receptor.
Rewcastle GW; Bridges AJ; Fry DW; Rubin JR; Denny WA
J Med Chem; 1997 Jun; 40(12):1820-6. PubMed ID: 9191958
[TBL] [Abstract][Full Text] [Related]
13. Tyrosine kinase inhibitors. 6. Structure-activity relationships among N- and 3-substituted 2,2'-diselenobis(1H-indoles) for inhibition of protein tyrosine kinases and comparative in vitro and in vivo studies against selected sulfur congeners.
Showalter HD; Sercel AD; Leja BM; Wolfangel CD; Ambroso LA; Elliott WL; Fry DW; Kraker AJ; Howard CT; Lu GH; Moore CW; Nelson JM; Roberts BJ; Vincent PW; Denny WA; Thompson AM
J Med Chem; 1997 Feb; 40(4):413-26. PubMed ID: 9046331
[TBL] [Abstract][Full Text] [Related]
14. 4-(Phenylamino)pyrrolopyrimidines: potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase.
Traxler PM; Furet P; Mett H; Buchdunger E; Meyer T; Lydon N
J Med Chem; 1996 Jun; 39(12):2285-92. PubMed ID: 8691423
[TBL] [Abstract][Full Text] [Related]
15. 2D Autocorrelation, CoMFA, and CoMSIA modeling of protein tyrosine kinases' inhibition by substituted pyrido[2,3-d]pyrimidine derivatives.
Caballero J; Fernández M; Saavedra M; González-Nilo FD
Bioorg Med Chem; 2008 Jan; 16(2):810-21. PubMed ID: 17964795
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative.
Buchdunger E; Zimmermann J; Mett H; Meyer T; Müller M; Druker BJ; Lydon NB
Cancer Res; 1996 Jan; 56(1):100-4. PubMed ID: 8548747
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of cell growth: effects of the tyrosine kinase inhibitor CGP 53716.
Major TC; Keiser JA
J Pharmacol Exp Ther; 1997 Oct; 283(1):402-10. PubMed ID: 9336349
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and structure-activity relationships of soluble 7-substituted 3-(3,5-dimethoxyphenyl)-1,6-naphthyridin-2-amines and related ureas as dual inhibitors of the fibroblast growth factor receptor-1 and vascular endothelial growth factor receptor-2 tyrosine kinases.
Thompson AM; Delaney AM; Hamby JM; Schroeder MC; Spoon TA; Crean SM; Showalter HD; Denny WA
J Med Chem; 2005 Jul; 48(14):4628-53. PubMed ID: 16000000
[TBL] [Abstract][Full Text] [Related]
19. RO4383596, an orally active KDR, FGFR, and PDGFR inhibitor: synthesis and biological evaluation.
McDermott LA; Simcox M; Higgins B; Nevins T; Kolinsky K; Smith M; Yang H; Li JK; Chen Y; Ke J; Mallalieu N; Egan T; Kolis S; Railkar A; Gerber L; Luk KC
Bioorg Med Chem; 2005 Aug; 13(16):4835-41. PubMed ID: 15953730
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of platelet-derived growth factor-mediated signal transduction and tumor growth by N-[4-(trifluoromethyl)-phenyl]5-methylisoxazole-4-carboxamide.
Shawver LK; Schwartz DP; Mann E; Chen H; Tsai J; Chu L; Taylorson L; Longhi M; Meredith S; Germain L; Jacobs JS; Tang C; Ullrich A; Berens ME; Hersh E; McMahon G; Hirth KP; Powell TJ
Clin Cancer Res; 1997 Jul; 3(7):1167-77. PubMed ID: 9815796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
